Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Obesity among patients with end-stage kidney disease (ESKD) contributes to cardiovascular risk, fluid overload, and transplant ineligibility. Weight reduction in this population remains a clinical challenge due to limited pharmacologic options and frequent intolerance to intensive ultrafiltration. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide are hepatically cleared and may be used in advanced chronic kidney disease. However, their effects in dialysis patients, particularly on residual renal function, remain undocumented.
We report a 62-year-old male with diabetic kidney disease on thrice-weekly hemodialysis for 14 months, anuric (<100 mL/day), and persistently obese (dry weight 108 kg, BMI > 35 kg/m²). Due to inadequate dialysis adequacy (Kt/V 0.89, URR 52.1%) and recurrent intradialytic hypotension from high ultrafiltration needs (~4 L/session), off-label semaglutide was initiated (0.25 mg → 0.5 mg → 1 mg weekly).
Over 12 weeks, the patient’s dry weight decreased from 108 kg to 93 kg, and urine output increased from <100 mL/day to 1.0–1.2 L/day. Dialysis adequacy improved (Kt/V 1.44; URR 71.5%), while ultrafiltration goals declined to 1–1.5 L/session without hemodynamic instability or medication adjustments. Mild transient nausea was the only reported side effect. The temporal association between semaglutide therapy, significant weight reduction, and restoration of diuresis suggests a possible physiologic effect beyond its metabolic actions.
Semaglutide may benefit obese hemodialysis patients beyond weight reduction, potentially improving residual renal function and dialysis tolerance. While causality cannot be established, this case highlights the potential dual action of GLP-1RAs in improving both metabolic control and residual renal function among obese ESKD patients. Further studies are warranted to confirm these findings.
